Teva Will Appeal Loss In Vigamox Eyecare Patent Suit

By Pete Brush

Law360, New York (November 20, 2009, 12:55 PM ET) -- Teva Pharmaceuticals USA Inc., having come out on the losing end in a three-year infringement struggle with Alcon Inc. over a patent related to the anti-bacterial eye drop drug Vigamox, has said it will keep up the fight in an appeal to the U.S. Court of Appeals for the Federal Circuit.

Judge Sue L. Robinson of the U.S. District Court for the District of Delaware entered final judgment against the U.S. arm of the Israel-based generics maker Oct. 20 after ruling that Teva's generic product infringed...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles